AstraZeneca will voluntarily withdraw the use of the company’s Imfinzi to treat advanced bladder cancer in the United States after the cancer drug failed to meet post-approval requirements, the Anglo-Swedish drugmaker said.
Shares of Cellectis Therapeutics were up in trading after the gene-editing pioneer company forged a deal with Cambridge, Mass.-based Cytovia Therapeutics to develop immunotherapies based on gene-edited allogeneic CAR T-cells.
Immunotherapy company 3T Biosciences picked John Connolly, Ph.D., as interim CEO.
Bristol Myers Squibb announced positive data from POETYK PSO-2, the second Phase III trial of deucravacitinib for moderate to severe plaque psoriasis, evaluated against placebo and Amgen’s Otezla (apremilast).
Gilead Sciences inked a collaboration, option and license deal with Gritstone Oncology to create a vaccine-based immunotherapy as a cure for HIV.
Merck KGaA’s drug development program suffered a setback with the company’s most important experimental medicine as the cancer treatment bintrafusp alfa, being jointly developed by GlaxoSmithKline, failed early in a lead trial.
Roche presented updated data confirming the Swiss drugmaker’s immunotherapy Tecentriq, used in combination with Avastin, substantially improves overall survival in people with the most common form of liver cancer.
Neoleukin was benched by the FDA with a clinical hold for the biopharma company’s lead cancer immunotherapy candidate.
San Diego-based Janux Therapeutics forged a strategic collaboration with pharma giant Merck potentially worth more than $1 billion to develop next-generation T cell engager immunotherapies for the treatment of cancer.
Days after Bayer announced a new cell and gene therapy strategy to maximize the capabilities of some recent acquisitions, the Germany-based life sciences giant is jumping into the CAR-T space and expanding the company’s oncology focus through a collaboration with Bay Area-based Atara Biotherapeutics.